Dana Flanders
Stock Analyst at Guggenheim
(0.11)
# 4,308
Out of 4,944 analysts
7
Total ratings
16.67%
Success rate
-20.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dana Flanders
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VALN Valneva SE | Maintains: Buy | $17 → $15 | $10.99 | +36.49% | 1 | Mar 24, 2025 | |
| SCYX SCYNEXIS | Initiates: Buy | $25 | $0.84 | +2,861.73% | 1 | Jan 22, 2021 | |
| PCRX Pacira BioSciences | Initiates: Neutral | n/a | $24.82 | - | 1 | May 27, 2020 | |
| HRTX Heron Therapeutics | Initiates: Buy | $24 | $1.33 | +1,704.51% | 1 | May 27, 2020 | |
| COLL Collegium Pharmaceutical | Initiates: Neutral | n/a | $38.00 | - | 1 | May 27, 2020 | |
| EBS Emergent BioSolutions | Upgrades: Buy | $60 → $75 | $9.01 | +732.87% | 2 | Nov 2, 2018 |
Valneva SE
Mar 24, 2025
Maintains: Buy
Price Target: $17 → $15
Current: $10.99
Upside: +36.49%
SCYNEXIS
Jan 22, 2021
Initiates: Buy
Price Target: $25
Current: $0.84
Upside: +2,861.73%
Pacira BioSciences
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $24.82
Upside: -
Heron Therapeutics
May 27, 2020
Initiates: Buy
Price Target: $24
Current: $1.33
Upside: +1,704.51%
Collegium Pharmaceutical
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $38.00
Upside: -
Emergent BioSolutions
Nov 2, 2018
Upgrades: Buy
Price Target: $60 → $75
Current: $9.01
Upside: +732.87%